A RANDOMIZED PHASE II STUDY (GISL-MM03 TRIAL) WITH ORAL MELPHALAN plus PREDNISONE (MP) VERSUS MELPHALAN, plus PREDNISONE plus THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

Stefano Sacchi(University of Modena and Reggio Emilia), Maura Brugiatelli(Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte), Raffaella Marcheselli, Gabriele Buda(Azienda Ospedaliera Universitaria Pisana), Nicola Di Renzo(Presidio Ospedaliero), O. Ciarcia, Alessia Bari, A. Pastorini, Antonio Lazzaro(Guglielmo da Saliceto Hospital), Maria Luigia Vigliotti(Ospedale Sant'Anna), Francesco Carlo Morabito(University of Reggio Calabria), A. Fragasso, Gianni Quarta, Luciano Masini(Casa di Cura Villa Garda), P. Musto(University of Indianapolis), Samantha Pozzi(University of Modena and Reggio Emilia)
IRIS UNIMORE (University of Modena and Reggio Emilia)
January 1, 2009
Cited by 1

Related Papers

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
|Journal of Clinical Oncology|2007|374
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
|Blood|2012|310
R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi
|Journal of Clinical Oncology|2013|262
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
|Proceedings of the National Academy of Sciences|2010|235